Found: 28
Select item for more details and to access through your institution.
Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies.
- Published in:
- Leukemia (08876924), 2012, v. 26, n. 5, p. 1119, doi. 10.1038/leu.2011.308
- By:
- Publication type:
- Article
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
- Published in:
- Leukemia (08876924), 2011, v. 25, n. 12, p. 1877, doi. 10.1038/leu.2011.165
- By:
- Publication type:
- Article
The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma.
- Published in:
- Leukemia (08876924), 2011, v. 25, n. 9, p. 1502, doi. 10.1038/leu.2011.112
- By:
- Publication type:
- Article
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
- Published in:
- Leukemia (08876924), 2010, v. 24, n. 7, p. 1343, doi. 10.1038/leu.2010.108
- By:
- Publication type:
- Article
Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.
- Published in:
- Bone Marrow Transplantation, 2013, v. 48, n. 10, p. 1302, doi. 10.1038/bmt.2013.53
- By:
- Publication type:
- Article
G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT.
- Published in:
- Bone Marrow Transplantation, 2013, v. 48, n. 2, p. 303, doi. 10.1038/bmt.2012.125
- By:
- Publication type:
- Article
Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.
- Published in:
- 2011
- By:
- Publication type:
- Correction notice
Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.
- Published in:
- Bone Marrow Transplantation, 2011, v. 46, n. 3, p. 350, doi. 10.1038/bmt.2010.118
- By:
- Publication type:
- Article
Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization.
- Published in:
- Bone Marrow Transplantation, 2011, v. 46, n. 2, p. 291, doi. 10.1038/bmt.2010.106
- By:
- Publication type:
- Article
CD34<sup>+</sup> cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.
- Published in:
- Bone Marrow Transplantation, 2010, v. 45, n. 12, p. 1699, doi. 10.1038/bmt.2010.49
- By:
- Publication type:
- Article
Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma.
- Published in:
- Bone Marrow Transplantation, 2010, v. 45, n. 9, p. 1396, doi. 10.1038/bmt.2009.370
- By:
- Publication type:
- Article
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.
- Published in:
- Bone Marrow Transplantation, 2010, v. 45, n. 3, p. 490, doi. 10.1038/bmt.2009.181
- By:
- Publication type:
- Article
Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma.
- Published in:
- Bone Marrow Transplantation, 2008, v. 41, n. 11, p. 919, doi. 10.1038/bmt.2008.82
- By:
- Publication type:
- Article
Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation.
- Published in:
- Bone Marrow Transplantation, 2008, v. 41, n. 8, p. 715, doi. 10.1038/sj.bmt.1705967
- By:
- Publication type:
- Article
Reply to ‘Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independence data set’ by Mark J Bishton et al.
- Published in:
- 2008
- By:
- Publication type:
- Letter
Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas.
- Published in:
- 2007
- By:
- Publication type:
- letter
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
- Published in:
- 2005
- By:
- Publication type:
- journal article
A phase I study of<sup>153</sup>Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
- Published in:
- Leukemia (08876924), 2005, v. 19, n. 1, p. 118, doi. 10.1038/sj.leu.2403575
- By:
- Publication type:
- Article
Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia.
- Published in:
- Bone Marrow Transplantation, 2006, v. 37, n. 11, p. 1003, doi. 10.1038/sj.bmt.1705369
- By:
- Publication type:
- Article
Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma.
- Published in:
- Bone Marrow Transplantation, 2006, v. 37, n. 11, p. 1017, doi. 10.1038/sj.bmt.1705371
- By:
- Publication type:
- Article
Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma.
- Published in:
- Bone Marrow Transplantation, 2006, v. 37, n. 9, p. 865, doi. 10.1038/sj.bmt.1705342
- By:
- Publication type:
- Article
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate.
- Published in:
- Bone Marrow Transplantation, 2004, v. 34, n. 12, p. 1025, doi. 10.1038/sj.bmt.1704691
- By:
- Publication type:
- Article
Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma.
- Published in:
- Bone Marrow Transplantation, 2004, v. 33, n. 3, p. 291, doi. 10.1038/sj.bmt.1704355
- By:
- Publication type:
- Article
Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma.
- Published in:
- Bone Marrow Transplantation, 2003, v. 32, n. 3, p. 317, doi. 10.1038/sj.bmt.1704124
- By:
- Publication type:
- Article
Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience.
- Published in:
- Bone Marrow Transplantation, 1998, v. 22, n. 10, p. 981, doi. 10.1038/sj.bmt.1701468
- By:
- Publication type:
- Article
IMPACT OF TIME TO RELAPSE AND RESPONSE TO SALVAGE THERAPY ON POST AUTOLOGOUS STEM CELL TRANSPLANT OUTCOMES IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.98_2880
- By:
- Publication type:
- Article
PROGRESSION‐FREE SURVIVAL AT 24 MONTHS AS A LANDMARK AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.97_2880
- By:
- Publication type:
- Article